1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Nov 2025
Admin
News Article

UCB Reports Sustained Three-Year Efficacy of BIMZELX® in Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, announced new three-year results from the BE HEARD clinical program evaluating BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa (HS). The findings showed sustained improvements in skin pain and resolution of draining tunnels, key disease features that significantly affect patient quality of life.

BIMZELX is the first and only approved therapy that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F).

Key Findings

Reduction of draining tunnels: Among patients with at least one draining tunnel at baseline, 48.2% had none after one year and 62.9% after three years.
Sustained remission: Of patients with no draining tunnels at baseline, 87.8% remained tunnel-free at one year and 90.8% at three years.
Skin pain improvement: The proportion of patients reporting no or mild pain increased from 10% at baseline to 51.7% after one year and 65.8% after three years.

“Reduction of draining tunnels and abscesses is key for patients with HS,” said Professor Steven Daveluy, Wayne State University. “These long-term data show sustained relief and suggest potential to reduce the structural damage that can occur over time.”

Donatello Crocetta, Chief Medical Officer at UCB, added that the results demonstrate “meaningful and durable improvements in inflammatory lesions and pain, highlighting BIMZELX’s long-term efficacy profile.”

About the Study

The post-hoc analysis included data from patients in the BE HEARD I & II Phase 3 trials who continued into the BE HEARD EXT open-label extension. The long-term results will be presented at the Symposium on Hidradenitis Suppurativa Advances (SHSA) 2025 in Nashville, Tennessee.

About Hidradenitis Suppurativa

HS is a chronic inflammatory skin disease marked by painful nodules, abscesses, and pus-draining tunnels, often leading to scarring and significant physical and psychological burden. The condition affects approximately 1% of the global population.

About BIMZELX®

BIMZELX is a humanized monoclonal antibody (IgG1) that selectively targets IL-17A and IL-17F, cytokines that drive inflammation. It is approved in the U.S. for adults with plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.

UCB is headquartered in Brussels, Belgium, with approximately 9,000 employees across 40 countries, and reported €6.1 billion in revenue in 2024.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!